Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

NIH Grants Sorrento Funding for Development of Small Molecule Inhibitor

By Drug Discovery Trends Editor | July 21, 2014

Sorrento Therapeutics Inc., a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced that it has received non-dilutive funding for the preclinical development of a small molecule inhibitor targeting the important oncogenic transcription factor Myc.
 
The Myc protein has also been recognized as an important determinant of cancer metabolism and protein synthesis. It is involved as a dominant factor in most human cancers and is rarely mutated, but rather its “gain of function” results from overexpression or gene amplification. Abnormal Myc activity is believed to play a substantial role in at least one out of every seven cancer deaths and is often a key factor in breast, lung, colon, hematologic, and other cancers.
 
Recent work on Myc highlighted the unexpected roles in cancers of nominally non-Myc etiology, such as KRAS-driven lung cancer, and also cellular resistance to PI3K inhibitors might be mediated by Myc activity. However, potent and selective small molecule Myc inhibitors have been very difficult to identify due to the structural characteristics of the Myc molecule.
 
Sorrento was awarded a Phase 1 Small Business Technology Transfer Research (STTR) grant from the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH), which will support the preclinical development of the Myc inhibitor, which interferes with the protein-protein interaction (PPI) between Myc and its obligatory dimerization partner, Max, preventing sequence-specific binding to DNA and subsequent initiation of oncogenic transformation.
 
The principal investigator on the STTR grant is Sorrento’s Senior Director of Research and Development Dr. Gunnar Kaufmann, and the academic collaborator is Dr. Kim Janda at The Scripps Research Institute (TSRI), a world-renowned chemical biologist and expert in PPI inhibitors. Earlier this year, Sorrento obtained an exclusive license from TSRI to the Myc inhibitors, the scientific foundation for this program.
 
Dr. Peter Vogt, EVP, CSO, & professor at TSRI, co-discoverer of the Myc, jun, PI3K, & src oncogenes, and Sorrento’s collaborator on this project, noted that “Myc has also been called the ’emperor of oncogenes.’ Targeting Myc with a small molecule inhibitor has been a daunting challenge and has given rise to the current dogma that Myc is ‘undruggable.’ Numerous studies have strengthened Myc’s candidacy as a promising cancer drug target and also suggest that Myc inhibition might be therapeutic in many or most cancer types, irrespective of the underlying driving oncogenic mechanism. This clearly enhances the significance and importance of this potential scientific breakthrough.”
 
The scientific details of these Myc inhibitors will be published in a forthcoming manuscript submitted by Dr. Janda, Vogt and their TSRI colleagues.
 
“While Sorrento’s focus will remain on developing our clinical stage assets Cynviloq and resiniferatoxin (RTX) as quickly and efficiently as possible, government-sponsored research allows us to explore innovative anti-cancer strategies, such as this potentially first-in-class Myc inhibitor. Our academic collaborators at TSRI and Sorrento’s research team will perform the preclinical studies needed to bring this program to an inflection point. We are very grateful for NCI’s support of this exciting and potentially paradigm-shifting program,” said Henry Ji, president and CEO of Sorrento.
 
Date: July 21, 2014
Source: Sorrento Therapeutics

Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE